Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma

BACKGROUND: Cutaneous melanoma is the most serious skin malignancy and new therapeutic strategies are needed for advanced melanoma. TP53 mutations are rare in cutaneous melanoma and hence activation of wild-type p53 is a potential therapeutic strategy in cutaneous melanoma. Here, we investigated the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Wu, Chiao-En, Esfandiari, Arman, Ho, Yi-Hsuan, Wang, Nan, Mahdi, Ahmed Khairallah, Aptullahoglu, Erhan, Lovat, Penny, Lunec, John
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2018
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5830592/
https://ncbi.nlm.nih.gov/pubmed/29235570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.433
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars